TICKERNERD
Menu
NXTSBasic Materials · Agricultural Inputs

NXTS Stock Forecast: Nexentis Technologies, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$0.65
−7.27% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 14 Oct 2026 — in the weakest quartile.

Market cap
$1.0M
Ticker Nerd rank
3 / 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$1.7M
Net income−$11.2M
Free cash flow−$623K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−39.6%
1M
−58.2%
YTD
−94.4%
1Y
−97.9%
From 52W high
−97.9%
From 52W low
0.0%
$1
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NXTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nexentis Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
3 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
100
Revisions
25
Momentum
18
Issuance
9
Accruals
8
Volatility
5
Growth
3
Quality
1
Value
1

Size (100): Smaller than most of the companies we track.

Value (1): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NXTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NXTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Jan 26Apr 26Jul 26Oct 26NXTS

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NXTS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NXTS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Nexentis Technologies, Inc. returned −97.9% against +17.5% for the S&P 500, dividends included.

NXTS vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26NXTSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NXTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Nexentis Technologies, Inc. (NXTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
0.5×

Cheaper than 83% of US stocks

EV / EBITDA
1.3×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−454.8%

Higher than 4% of US stocks

Return on assets
−29.5%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Nexentis Technologies, Inc. (NXTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Nexentis Technologies, Inc. has a market value of $1.0M and an enterprise value of −$7.6M.

  • Revenue in the twelve months to 30 June 2026: −$66K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$16.1M, a 24454.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$4.2M.

  • Shares outstanding: 1.5M.

  • Trailing P/E: 0.1×.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Nexentis Technologies, Inc. employs 7 people — −$9K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

NXTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelAgricultural Inputs
CompanyMarket capTKN rank
NXTSNexentis Technologies, Inc.$1.0M
3
SEEDOrigin Agritech Ltd.$9.7M
23
BIOXBioceres Crop Solutions Corp.$19.0M
28
AVDAmerican Vanguard Corp.$32.3M
38
CAPSCapstone Holding Corp.*$3.1M
31
CNEYCN Energy Group, Inc.*$3.3M
20
SNESSenesTech, Inc.*$3.4M
30

* Nearest Basic Materials names by size — few agricultural inputs companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nexentis Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NXTS news & analysis

Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud

GlobeNewsWire · 7 Oct 2026positive

MitoCareX Bio deployed its computational drug discovery infrastructure on Google Cloud Platform. The deployment is designed to enhance computational capacity, data governance, and operational flexibility as the company advances its drug discovery programs.

Why it matters — NXTS watchers may note the cloud deployment as an infrastructure development supporting MitoCareX Bio’s drug discovery programs.

Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

GlobeNewsWire · 24 Sept 2026positive

Nexentis Technologies announced that Prof. Dan T. Major, a leading computational chemistry expert, has been appointed to the Scientific Advisory Board of its subsidiary MitoCareX. Prof. Major will advise MitoCareX as it expands its in silico (computational) drug-discovery capabilities.

Why it matters — NXTS watchers may see this appointment as strengthening MitoCareX's computational drug-discovery capabilities, potentially enhancing the company's drug development efforts.

Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery

GlobeNewsWire · 23 Sept 2026positive

MitoCareX is evaluating additional commercially available approaches for obtaining proteins, with the goal of enhancing access to research materials, increasing research flexibility, and supporting the advancement of its future in-vitro drug discovery programs.

Why it matters — A Nexentis watcher would care because expanded protein sourcing capabilities could support the flexibility and future progress of MitoCareX's in-vitro drug discovery programs.

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

GlobeNewsWire · 28 July 2026positive

Nexentis Technologies subsidiary MitoCareX Bio has selected a prioritized transport protein candidate for its drug discovery campaign, following a broad structural analysis of the human SLC transport protein family. The selection reflects continued execution of MitoCareX's MITOLINE®-driven discovery strategy.

Why it matters — For NXTS watchers, this milestone indicates the subsidiary is advancing its pipeline by narrowing candidates to a specific target, demonstrating progress in its drug discovery efforts.

FAQ

Frequently asked questions about NXTS stock

How does Ticker Nerd's model rank NXTS?

As at 14 Oct 2026, Nexentis Technologies, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).

What is the NXTS stock forecast for 2030?

No analyst covering Nexentis Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NXTS are extrapolating price history, which says nothing about the business.

How has NXTS stock performed over the past year?

Nexentis Technologies, Inc. returned -97.9% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nexentis Technologies, Inc. do?

Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects.

What is the latest news on NXTS?

The most recent item we track (GlobeNewsWire, 7 Oct 2026): "Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud". MitoCareX Bio deployed its computational drug discovery infrastructure on Google Cloud Platform. The deployment is designed to enhance computational capacity, data governance, and operational flexibility as the company advances its drug discovery programs.

Company

About Nexentis Technologies, Inc.

Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.

7 employees · Israel · https://www.nexentistech.com